Y. Tamboli et al. / Bioorg. Med. Chem. Lett. 22 (2012) 3810–3815
3815
(3H, t, -CH2CH2CH2CH3), 1.13–1.32 (4H, m, -CH2CH2CH2CH3), 2.93 (2H, q, -
CH2CH2CH2CH3), 4.41–4.56 (2H, m, -OCH2-), 4.91–5.10 (2H, m, -CH2ONO2),
5.81–5.85 (1H, m, -CHONO2), 6.42 (1H, t, -NHCH2-), 7.15 (2H, d, Arom), 7.86
(2H, d, Arom), 10.42 (1H, s, -SO2NH-); 13C NMR (DMSO-d6) d 14.0, 19.8, 31.7,
39.1, 65.9, 70.3, 78.2, 115.1, 130.0, 133.2, 151.8, 166.7; MS (CI) m/z 437 (M+1)+.
Compound 11: yield: 15%. M.p. = 160 °C (from EtOH). 1H NMR (DMSO-d6) d
0.80 (3H, t, -CH2CH2CH2CH3), 1.10–1.33 (4H, m, -CH2CH2CH2CH3), 2.95 (2H, q, -
CH2CH2CH2CH3), 6.52–6.56 (1H, m, -NHCH2-), 7.67 (2H, d, Arom), 7.76 (2H, t,
Arom), 7.89–8.02 (5H, m, Arom), 10.67 (1H, s, -SO2NH-); 13C-NMR (DMSO-d6) d
13.8, 19.6, 31.5, 39.1, 111.7, 119.9, 128.9, 130.10, 130.2, 136.6, 137.0, 138.2,
151.5, 156.2, 157.6; MS (CI) m/z 497 (M+1)+. Compound 19: yield: 89%.
M.p. = 156.5 °C (from EtOH/H2O 1/1 v/v). 1H NMR (DMSO-d6) d 0.81 (3H, t, -
J.; Simeonov, A.; Maloney, D. J.; Williams, D. L.; Thomas, C. J. J. Med. Chem. 2009,
52, 6474.
22. Venous blood samples were obtained from healthy volunteers who had not
taken any drugs for at least 2 weeks. Volunteers, who were treated according to
the Helsinki protocol for biomedical experimentation, gave their informed
consent to the use of blood samples for research purposes. PRP was prepared
by centrifugation of citrated blood at 210g for 20 min. Aliquots (500 lL) of PRP
were added into aggregometer (Chrono-log 4902D) cuvettes, and aggregation
was recorded as increased light transmission under continuous stirring
(1000 rpm) at 37 °C for 10 min after the addition of the stimulus. Collagen at
submaximal concentrations (0.8–1.5 lg/mL) was used as the platelet activator
in PRP. Compounds under study were preincubated with PRP 10 min before the
addition of the stimulus (collagen). Vehicle alone (0.5% DMSO) added to PRP
did not affect platelet function in control samples. The role of NO and sGC in
CH2CH2CH2CH3), 1.10–1.34 (4H, m, -CH2CH2CH2CH3), 2.93 (2H, q,
-
CH2CH2CH2CH3), 5.57 (2H, s, -OCH2-), 6.44 (1H, t, -NHCH2-), 7.23 (2H, d,
Arom), 7.57–7.62 (3H, m, Arom), 7.83–7.86 (4H, m, Arom), 10.47 (1H, s, -
SO2NH-); 13C NMR (DMSO-d6) d 13.4, 19.2, 31.2, 38.7, 61.3, 114.3, 115.0, 121.9,
127.6, 129.0, 129.4, 130.7, 133.2, 151.0, 153.7, 160.4; MS (CI) m/z 447 (M+1)+.
Compound 20: yield: 27%. M.p. = 182 °C (from EtOH). 1H NMR (DMSO-d6) d
0.90 (3H, t, -CH2CH2CH2CH3), 1.11–1.35 (4H, m, -CH2CH2CH2CH3), 2.94 (2H, q, -
CH2CH2CH2CH3), 5.53 (2H, s, -OCH2-), 6.43 (1H, t, -NHCH2-), 7.24 (2H, d, Arom),
7.78 (1H, s, -SO2NH-), 7.80 (2H, d, Arom), 8.50 (1H, s br, -CONH2), 10.44 (1H, s
br, -CONH2); 13C NMR (DMSO-d6) d 13.6, 19.3, 31.3, 38.7, 61.5, 110.5, 114.9,
129.5, 133.0, 151.4, 154.9, 155.7, 160.9; MS (CI) m/z 414 (M+1)+. Compund 21:
yield: 86%. M.p. = 160 °C (from EtOH/H2O 1/1 v/v). 1H NMR (DMSO-d6) d 0.92
(3H, t, -CH2CH2CH2CH3), 1.11–1.34 (4H, m, -CH2CH2CH2CH3), 2.94 (2H, q, -
CH2CH2CH2CH3), 5.62 (2H, s, -OCH2-), 6.44 (1H, t, -NHCH2-), 7.32 (2H, d, Arom),
7.92 (2H, d, Arom), 10.47 (1H, s, -SO2NH-); 13C NMR (DMSO-d6) d 13.4, 19.2,
31.2, 38.7, 60.8, 98.2, 106.2, 114. 9, 129.5, 133.4, 151.2, 154.4, 160.2; MS (CI) m/
z 396 (M+1)+.
the inhibitory effect was investigated using ODQ (50 lM). At least four
experiments for each compound were performed. The anti-aggregatory activity
of tested compounds is evaluated as percent inhibition of platelet aggregation
compared to control samples. For most active compounds, IC50 values could be
calculated by nonlinear regression analysis; otherwise, percent inhibition at
the maximal concentration tested (300 lM) is reported.
23. Weber, A. A.; Neuhaus, T.; Seul, C.; Dusing, R.; Schror, K.; Sachinidis, A.; Vetter,
H. Eur. J. Pharmacol. 1996, 309, 209.
24. Proks, P.; Reimann, F.; Gribble, F.; Ashcroft, F. Diabetes 2002, 51(Suppl 3), S368.
25. Merglen, A.; Theander, S.; Rubi, B.; Chaffard, G.; Wollheim, C. B.; Maechler, P.
Endocrinology 2004, 145, 667.
26. Cell culture: INS-1E cells were cultured in a humidified atmosphere containing
5% CO2 in complete medium composed of RPMI 1640 supplemented with 10%
heat-inactivated fetal calf serum, 1 mM sodium pyruvate, 50
mercaptoethanol, 2 mM glutamine, 10 mM HEPES, 100 U/ml penicillin and
100 g/ml streptomycin. The maintenance culture was passaged once a week
lM 2
18. Mitsunobu, O. Synthesis 1981, 1, 1.
l
19. Fruttero, R.; Crosetti, M.; Chegaev, K.; Guglielmo, S.; Gasco, A.; Berardi, F.; Niso,
M.; Perrone, R.; Panaro, M. A.; Colabufo, N. A. J. Med. Chem. 2010, 53, 5467.
20. Thoracic aortas were isolated from male Wistar rats weighing 180–200 g
(Harlan Italy Laboratories, S. Pietro al Natisone, Italy). As few animals as
possible were used. The purposes and the protocols of our studies have been
approved by Ministero della Salute, Rome, Italy. The endothelium was
removed; the vessels were helically cut and four to six strips were obtained
from each aorta. The tissues were mounted under 1.0 g of tension in organ
baths containing 30 mL of Krebs-bicarbonate buffer with the following
composition: 111.2 mM NaCl, 5.0 mM KCl, 2.5 mM CaCl2, 1.2 mM MgSO4,
1.0 mM KH2PO4, 12.0 mM NaHCO3, and 11.1 mM glucose, maintained at 37 °C
and gassed with 95:5% O2/CO2 (pH 7.4). The aortic strips were allowed to
by gentle trypsinisation.
Insulin secretion: The secretory response to glucose and other secretagogues
was tested in INS-1E cells between passages 54 and 65. Cells were seeded in
24-well plates at a density of 4 Â 104 cells/cm2 in RPMI medium. After 48 h,
medium was removed and cells were pre-incubated for 1 h at 37 °C in Krebs-
Ringer bicarbonate buffer with HEPES (KRBH) containing 0.5% bovine serum
albumin (BSA, fraction V, Sigma) and basal glucose concentrations (1 or 2 mM,
according to the protocol). At the end of the pre-incubation time, cells were
washed and then incubated for 1 h at 37 °C in 1 mL fresh KRBH buffer
containing 0.5% BSA and suitable glucose concentrations, in the presence or
absence of tolbutamide and its derivatives, used at concentrations of 100 or
200 lM. At the end of the incubation, the buffer was collected for insulin
equilibrate for 120 min and then contracted with 1
the response to the agonist reached a plateau, cumulative concentrations of the
vasodilating agent were added. Results are expressed as EC50 SEM ( M). The
effects of 1 M ODQ upon relaxation were evaluated in a separate series of
lM
L-phenylephrine. When
determination. Finally, 1 mL of cold acidified ethanol (150:47:3, v/v, absolute
ethanol/H2O/concentrated HCl) was added to the cells and left for 24 h in order
to extract their insulin content.
Insulin was measured in the buffer and in the acid-ethanol extract by
radioimmunoassay according to Herbert et al. (Herbert V.; Lau K. S.; Gottlied
C.W.; Bleicher S. J. Coated charcoal immunoassay of insulin. J. Clin. Endocrinol.
1965, 25, 1375), using rat insulin as a standard. The sensitivity and the
coefficient of variation of the radioimmunoassay were as follows: detection
limit 0.13 ng/mL, intra-assay variation 3.3%, inter-assay variation 10.5%.
l
l
experiments, in which ODQ was added to the organ bath 5 min before the
contraction. Responses were recorded by an isometric transducer connected to
the MacLab System PowerLab. The addition of the drug vehicle (DMSO) had no
appreciable effect on the contraction level. At least five experiments for each
compound were perfomed.
21. Rai, G.; Sayed, A. A.; Lea, W. A.; Luecke, H. F.; Chakrapani, H.; Prast-Nielsen, S.;
Jadhav, A.; Leister, W.; Shen, M.; Inglese, J.; Austin, C. P.; Keefer, L.; Arner, E. S.